ROS-Sensitive Nanoparticles Co-delivering Dexamethasone and CDMP-1 for the Treatment of Osteoarthritis Through Chondrogenic Differentiation Induction and Inflammation Inhibition.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

1. Dual-functional ROS-responsive hydrogel alleviates temporomandibular joint osteoarthritis by enhancing cartilage repair and mitigating inflammation.Materials today. Bio · 2025
   Article
2. Stimuli-Responsive Nanomedicines for the Treatment of Non-cancer Related Inflammatory Diseases.ACS nano · 2025
   Review
3. Nanomaterial-Based Drug Delivery Systems Targeting Functional Cells for Osteoarthritis Treatment: Mechanisms, Challenges and Future Prospects.International journal of nanomedicine · 2025
   Review
4. Evolving functional hydrogel strategies for cartilage engineering: from fundamentals to functional regeneration.Burns & trauma · 2025
   Review
5. Controlled Stimulus-Responsive Delivery Systems for Osteoarthritis Treatment.International journal of molecular sciences · 2024
   Review
6. The potential role of synovial cells in the progression and treatment of osteoarthritis.Exploration (Beijing, China) · 2023
   Review
7. Intra-articular nanoparticles based therapies for osteoarthritis and rheumatoid arthritis management.Materials today. Bio · 2023
   Article
8. ROS-responsive PPGF nanofiber membrane as a drug delivery system for long-term drug release in attenuation of osteoarthritis.NPJ Regenerative medicine · 2022
   Article
9. Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs.Trends in pharmacological sciences · 2022
   Review
10. Recent Advances in Reactive Oxygen Species (ROS)-Responsive Polyfunctional Nanosystems 3.0 for the Treatment of Osteoarthritis.Journal of inflammation research · 2022
    Review
11. Therapeutic potential of nanotechnology-based approaches in osteoarthritis.Frontiers in pharmacology · 2022
    Review
12. TP53-mediated miR-2861 promotes osteogenic differentiation of BMSCs by targeting Smad7.Molecular and cellular biochemistry · 2022
    Article
13. Knee Osteoarthritis Therapy: Recent Advances in Intra-Articular Drug Delivery Systems.Drug design, development and therapy · 2022
    Review
14. Current Insights Into the Maintenance of Structure and Function of Intervertebral Disc: A Review of the Regulatory Role of Growth and Differentiation Factor-5.Frontiers in pharmacology · 2022
    Review
15. Ciprofloxacin-Releasing ROS-Sensitive Nanoparticles Composed of Poly(Ethylene Glycol)/Poly(D,L-lactide-co-glycolide) for Antibacterial Treatment.Materials (Basel, Switzerland) · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as